Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: TG-1031, Transgene SA.

C Doehn1, D Jocham

  • 1Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany. doehn@medinf.mu-luebeck.de

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].

Urologie (Heidelberg, Germany)·2024
Same author

[Update of the German S3 guideline on renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

Der Urologe. Ausg. A·2021
Same author

[Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?]

Der Urologe. Ausg. A·2020
Same author

[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma].

Der Urologe. Ausg. A·2020
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

This study explores VV-MUC1-IL-2 (TG-1031), a novel cancer immunotherapy targeting tumor antigen MUC1 and using a vaccinia virus vector. This approach shows promise for treating adenocarcinomas like breast and prostate cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Tumor-associated antigens are promising diagnostic, prognostic, and therapeutic targets.
  • MUC1 is a transmembrane glycoprotein expressed in most glandular epithelial cells, making it a relevant tumor antigen.
  • Active and passive immunotherapies are advancing cancer treatment strategies.

Purpose of the Study:

  • To evaluate the potential of VV-MUC1-IL-2 (TG-1031) as an antigen-specific cancer immunotherapy.
  • To investigate the use of vaccinia virus vectors for stimulating immune responses against tumor antigens.
  • To explore the efficacy of TG-1031 in treating adenocarcinomas.

Main Methods:

  • Development of VV-MUC1-IL-2 (TG-1031), combining MUC1 antigen, IL-2, and a vaccinia virus vector.

Related Experiment Videos

  • Utilizing vaccinia virus vectors known to elicit strong immune responses to encoded antigens.
  • Conducting phase I and II clinical trials to assess safety and preliminary efficacy.

    • Main Results:

    • Vaccinia virus vectors effectively stimulate in vivo immune responses against encoded antigens.
    • TG-1031 therapy integrates tumor antigen MUC1 with immune-stimulating cytokine IL-2.
    • Ongoing clinical trials are investigating the therapeutic potential of this novel approach.

    Conclusions:

    • VV-MUC1-IL-2 (TG-1031) represents a promising antigen-specific immunotherapy for various adenocarcinomas.
    • The combination of MUC1 antigen, IL-2, and vaccinia virus vector warrants further investigation in clinical settings.
    • This therapy holds potential for treating breast cancer, prostate cancer, and other epithelial-derived malignancies.